Cell-free DNA — Minimally invasive marker of hematological malignancies

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

KUBACZKOVÁ Veronika VRÁBEL Dávid SEDLAŘÍKOVÁ Lenka BEŠŠE Lenka ŠEVČÍKOVÁ Sabina

Year of publication 2017
Type Article in Periodical
Magazine / Source European Journal of Haematology
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1111/ejh.12925
Field Oncology and hematology
Keywords acute lymphoblastic leukemia; acute myeloid leukemia; multiple myeloma; myelodysplastic syndromes
Description Although tumor cells are the most reliable source of tumor DNA, biopsy of the tumor is an invasive procedure that should be avoided in some cases. The main limitation of any biopsy is sampling of one tumor site, which may not represent all malignant clones due to the heterogeneity of the tumor. These clones respond to treatment differently and thus directly influence survival of the patient. Circulating cell-free DNA (cfDNA) is released from multiple tumor sites, reflects overall heterogeneity of the tumor, and correlates with its progression. Detection of tumor-specific genetic and epigenetic aberrations in cfDNA could have a direct impact on molecular diagnosis, prognosis, follow-up of disease, monitoring of minimal residual disease, and response to treatment. While most cfDNA data are still experimental, they are very promising. This review focuses on cfDNA in hematological malignancies.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info